세계의 경구 단백질 및 펩타이드 시장 : 유효 성분별, 제제 유형별, 딜리버리 기술별, 치료 적응증별, 지역별, 기회 및 예측(2018-2032년)

Global oral proteins and peptides market is projected to witness a CAGR of 13.66% during the forecast period 2025-2032, growing from USD 6.67 billion in 2024 to USD 18.58 billion in 2032. Oral proteins and peptides are therapeutic biomolecules taken through the mouth in the form of tablets and capsules instead of injections.

Oral peptides and proteins are experiencing substantial market growth worldwide because of better medical delivery techniques combined with growing patient interest in accessible therapeutic solutions. Oral protein and peptide treatment has become the preferred option for patients who manage chronic conditions because of its simplicity over injectable medications. The treatment of diabetes alongside cancer and gastrointestinal disorders benefits greatly from oral peptide formulations because they provide better therapeutic outcomes and improved drug absorption.

The development of innovative encapsulation technologies and penetration enhancers has successfully resolved nutritional absorption difficulties and enzymatic degradation problems that lasted for a long time. Leading pharmaceutical companies dedicate substantial funding to research and development to grow their product lines while establishing strategic alliances with biotechnology organizations to speed up market entry.

The healthcare systems of North America and Europe lead the market because of their strong infrastructure and their ability to invest heavily in medical research. The healthcare domain of the Asia-Pacific region shows promising growth prospects because of increased healthcare awareness combined with growing investment activities in the region.

Market growth will continue despite regulatory complexity and manufacturing challenges since chronic diseases keep increasing, and the healthcare industry is moving toward personalized medicine delivery systems. For instance, in 2023, Eli Lilly and Company purchased Dice Therapeutics for USD 2.4 billion to demonstrate their deep interest in oral peptide therapy, especially for IL-17 inhibitors, which treat autoimmune conditions. The industry demonstrates a movement toward new treatment options, which patients find more convenient than injectable drugs.

Rising Prevalence of Chronic Disease Boosts Market Demand

The rising prevalence of chronic disease is increasing due to diabetes, cardiovascular disorders, obesity, and gastrointestinal conditions, which will boost the need for oral proteins and peptides as a more user-friendly treatment alternative to injections. The healthcare system faces a growing disease burden because of modern sedentary living habits, which are paired with unhealthy eating patterns and rising stress levels while dealing with an aging population. For instance, according to the International Diabetes Federation, about 539 million adults are currently dealing with diabetes, and the number is expected to increase to 853 million by the year 2050. The growing diabetes epidemic supports the increased market sales of oral peptide therapeutics such as GLP-1 agonists.

Furthermore, cancer and autoimmune diseases are also less common, and advanced biologic treatments are needed as the second line of treatment. With compliance factors encountered with injectable biologics, traditional injectable alternatives are an attractive option for continuous, long-term treatment. Health providers and governments are putting patients first, which is driving R&D to deliver oral protein more quickly. These trends quickly require innovative, non-invasive therapies to prevent chronic disease and boost market demand effectively.

Advancement in Drug Discovery Technology to Uplift Market Expansion

Expected growth in the oral proteins and peptides market will be fueled by modern advancements in drug discovery techniques. New technologies such as AI-enabled drug design, high-throughput screening, and computational modeling support the identification of peptides closer to any notion of stability and bioavailability. New delivery systems such as nanoparticle carriers and permeation enhancers allow peptides to overcome traditional challenges, including poor absorption and enzymatic degradation after oral administration. Formulation technologies such as enteric coatings and protease inhibitors improve oral bioavailability as well. In addition, biotech companies are also tapping into unique CRISPR and mRNA platforms to develop next-generation peptide therapeutics.

Additionally, key players are focusing on advanced technology for the development of oral proteins and peptides. For instance, in June 2024, Biora Therapeutics, Inc. announced the results of preclinical trials of its latest technology, the BioJet Systemic Oral Delivery Platform, at the Next Gen Peptide Formulation & Delivery conference. This technology is used as an ingestible device designed to transit through the digestive system and activate in the small intestine. Such advanced technology increased the potential of oral protein and peptides therapies in targeted delivery, by providing alternatives to injections and expanding the uses of various medical treatments.

Tablets Hold the Largest Market Share of the Oral Protein and Peptides Market

The oral protein and peptides market is dominated by tablets due to limitations of the oral form of protein and peptides, so they are most common. Tablets' unique solid dosage form allows a lot more convenience in administration, provides longer shelf stability than liquids or powders, with precise dosage, and if needed, doesn't need to be refrigerated. Innovations (technologies) in formulating biomolecules (enteric and controlled release formulation technologies) have impacted biologically sensitive biomolecules and their capability to produce sensitive biomolecules and novel forms of sensitive biologic oral delivery. Tablets are also less expensive to manufacture and ship than a vial or liquid drug, which makes them the most developed and accepted delivery form for pharmaceutical companies, because there are accepted manufacturing, distribution, and marketing pathways for tablets. While there are some alternative formats also available today (i.e., capsules, oral films), tablets or solid dosage forms are the historically most trusted and accepted dosage form for chronic treatments (demand for protein and peptide delivery by the oral route).

For instance, in April 2025, Merck & Co., Inc. announced that peptide drugs may soon be available in convenient oral tablet form through a USD 493 million licensing deal with Austria-based drug delivery technology maker Cyprumed.

North America Dominates the Oral Proteins and Peptides Market

North America is dominant in the global oral proteins and peptides market due to its cutting-edge healthcare infrastructure, strong research and development capabilities, and high demand for advanced biological therapies. The established pharmaceutical sector, along with flexible regulations in this region, allows quick development and market entry of novel oral protein-based medical solutions. The increasing occurrence of chronic diseases, especially diabetes and gastrointestinal disorders, creates a growing market for convenient oral peptide treatment options. North America strengthens its market leadership through major biotechnology investments and the rising popularity of non-invasive drug delivery methods. The region remains dominant in the emerging oral proteins and peptides industry through continuous drug formulation technology combined with expanding clinical applications.

Additionally, most of the pharmaceutical companies' headquarters are in North America. Along with the key industry players, numerous medical research organizations are propelling market growth by launching new products or innovative research. For instance, in February 2024, Johnson & Johnson Services, Inc., presented phase 2b FRONTIER 1 trial results for JNJ-2113, the first oral peptides under development for the treatment of moderate to severe plaque psoriasis (PsO).

Impact of U.S. Tariffs on Oral Proteins and Peptides Market

The global protein and peptide market shows significant disruptions due to the U.S. tariff implementation because it affects supply networks and generates cost spikes for manufacturers and end consumers. Organizations today need to select between absorbing their higher expenses and shifting these costs to their customers because current elevated tariffs apply to finished goods and raw materials, resulting in lower market effectiveness. The economic effects of U.S. import changes have generated difficulties for developing countries that rely heavily on American products, so these nations have begun to change their trading approaches and discover fresh supply chain options. The implementation of new tariffs has both encouraged local production development and produced financial challenges for small enterprises to handle their debts. The new policy introduces market instability that lowers growth trajectories while it demands that business stakeholders make strategic adjustments for the altered trade conditions.

Key Players Landscape and Outlook

The leading participants within the oral protein and peptides sector apply various tactics to enhance their market standing and maintain their long-term sustainability. Companies are investing in research and development alongside strategic partnerships and market expansion efforts to fuel their innovative activities in this sector. Companies protect their competitive position by obtaining exclusive rights through patent registration that enables them to maintain market control. The companies choose to work with local manufacturers in emerging markets to achieve two important objectives, which include lowering costs and expanding treatment availability to more patients.

For instance, in February 2025, Oramed Pharmaceuticals Inc. announced a joint venture with Hefei Tianhui Biotech Co. Ltd. to spin off its Protein Oral Delivery technology, which aims to redefine diabetes care and transform the future of oral biologics and chronic disease management.

For instance, in December 2024, Merck & Co., Inc. and Hansoh Pharma jointly announced that they are entering into a global licensing agreement for HS-10535, an investigational oral GLP-1 receptor agonist.

For instance, in May 2025, Novo Nordisk A/S is preparing to launch its Wegovy, a blockbuster weight loss medication, in the upcoming years 2026 for the treatment of obesity.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Oral Proteins and Peptides Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Active Ingredient
    • 5.2.1.1. Semaglutide
    • 5.2.1.2. Linaclotide
    • 5.2.1.3. Calcitonin
    • 5.2.1.4. Octreotide
    • 5.2.1.5. Others
  • 5.2.2. Formulation Type
    • 5.2.2.1. Tablets
    • 5.2.2.2. Capsules
    • 5.2.2.3. Oral Suspensions/Solutions
  • 5.2.3. By Delivery Technology
    • 5.2.3.1. Enteric Coating Systems
    • 5.2.3.2. Nanoparticle/Carrier-Based Delivery
    • 5.2.3.3. Mucoadhesive Technologies
    • 5.2.3.4. Others
  • 5.2.4. By Therapeutic Indication
    • 5.2.4.1. Diabetes Mellitus
    • 5.2.4.2. Gastrointestinal Disorders
    • 5.2.4.3. Bone Metabolic Diseases
    • 5.2.4.4. Endocrine Disorders
    • 5.2.4.5. Genetic and Rare Diseases
    • 5.2.4.6. Others
  • 5.2.5. By Region
    • 5.2.5.1. North America
    • 5.2.5.2. Europe
    • 5.2.5.3. Asia-Pacific
    • 5.2.5.4. South America
    • 5.2.5.5. Middle East and Africa
  • 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Active Ingredient
  • 5.3.2. By Formulation Type
  • 5.3.3. By Delivery Technology
  • 5.3.4. By Therapeutic Indication
  • 5.3.5. By Region

6. North America Oral Proteins and Peptides Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Active Ingredient
    • 6.2.1.1. Semaglutide
    • 6.2.1.2. Linaclotide
    • 6.2.1.3. Calcitonin
    • 6.2.1.4. Octreotide
    • 6.2.1.5. Others
  • 6.2.2. Formulation Type
    • 6.2.2.1. Tablets
    • 6.2.2.2. Capsules
    • 6.2.2.3. Oral Suspensions/Solutions
  • 6.2.3. By Delivery Technology
    • 6.2.3.1. Enteric Coating Systems
    • 6.2.3.2. Nanoparticle/Carrier-Based Delivery
    • 6.2.3.3. Mucoadhesive Technologies
    • 6.2.3.4. Others
  • 6.2.4. By Therapeutic Indication
    • 6.2.4.1. Diabetes Mellitus
    • 6.2.4.2. Gastrointestinal Disorders
    • 6.2.4.3. Bone Metabolic Diseases
    • 6.2.4.4. Endocrine Disorders
    • 6.2.4.5. Genetic and Rare Diseases
    • 6.2.4.6. Others
  • 6.2.5. By Country Share
    • 6.2.5.1. United States
    • 6.2.5.2. Canada
    • 6.2.5.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Oral Proteins and Peptides Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Active Ingredient
        • 6.3.1.2.1.1. Semaglutide
        • 6.3.1.2.1.2. Linaclotide
        • 6.3.1.2.1.3. Calcitonin
        • 6.3.1.2.1.4. Octreotide
        • 6.3.1.2.1.5. Others
      • 6.3.1.2.2. By Formulation Type
        • 6.3.1.2.2.1. Tablets
        • 6.3.1.2.2.2. Capsules
        • 6.3.1.2.2.3. Oral Suspensions/Solutions
      • 6.3.1.2.3. By Delivery Technology
        • 6.3.1.2.3.1. Enteric Coating Systems
        • 6.3.1.2.3.2. Nanoparticle/Carrier-Based Delivery
        • 6.3.1.2.3.3. Mucoadhesive Technologies
        • 6.3.1.2.3.4. Others
      • 6.3.1.2.4. By Therapeutic Indication
        • 6.3.1.2.4.1. Diabetes Mellitus
        • 6.3.1.2.4.2. Gastrointestinal Disorders
        • 6.3.1.2.4.3. Bone Metabolic Diseases
        • 6.3.1.2.4.4. Endocrine Disorders
        • 6.3.1.2.4.5. Genetic and Rare Diseases
        • 6.3.1.2.4.6. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Oral Proteins and Peptides Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Oral Proteins and Peptides Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Oral Proteins and Peptides Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Oral Proteins and Peptides Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Supply Chain Analysis

13. Value Chain Analysis

14. Porter's Five Forces Analysis

15. PESTLE Analysis

16. Pricing Analysis

17. Market Dynamics

• 17.1. Market Drivers
• 17.2. Market Challenges

18. Market Trends and Developments

19. Regulatory Framework

• 19.1. Regulatory Approval Scenario
• 19.2. Regulatory Approvals

20. Patent Landscape

21. Case Studies

22. Competitive Landscape

• 22.1. Competition Matrix of Top 5 Market Leaders
• 22.2. SWOT Analysis for Top 5 Players
• 22.3. Key Players Landscape for Top 10 Market Players
  • 22.3.1. Novo Nordisk A/S
    • 22.3.1.1. Company Details
    • 22.3.1.2. Key Management Personnel
    • 22.3.1.3. Products and Services
    • 22.3.1.4. Financials (As Reported)
    • 22.3.1.5. Key Market Focus and Geographical Presence
    • 22.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 22.3.2. Pfizer Inc.
  • 22.3.3. AbbVie Inc.
  • 22.3.4. Merck & Co., Inc.
  • 22.3.5. Johnson & Johnson Services, Inc.
  • 22.3.6. Biocon Limited
  • 22.3.7. Synergy Pharmaceuticals Inc.
  • 22.3.8. Oramed Pharmaceuticals Inc.
  • 22.3.9. Acadia Pharmaceuticals Inc.
  • 22.3.10. Proxima Concepts Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

23. Strategic Recommendations

24. About Us and Disclaimer